News & Media

Basser Executive Director Susan Domchek, MD, received a Fellow of the American Society of Clinical Oncology distinction at the American Society of Clinical Oncology annual meeting.

Findings to be presented during a plenary session at the American Society of Clinical Oncology meeting show that a PARP inhibitor significantly reduced the risk that breast cancer would return when given to patients with the BRCA mutation.

Many pancreatic cancer patients with BRCA mutations saw their tumors stop growing or shrink substantially after being switched from chemotherapy to the PARP inhibitor rucaparib, according to results from a clinical trial led by the Basser Center.

Susan Domchek, MD, Basser Center Executive Director, was quoted in a Wall Street Journal article that profiled a woman’s experience with genetic testing and a surprising family tree that led her to make decisions about her cancer care.

Philly Voice highlights our Black & BRCA initiative, which launched last fall to help raise awareness about genetic testing in the Black community. 

Ambiguous Genetic Test Results Can Be Unsettling. Worse, They Can Lead to Needless Surgeries

Next-Generation Sequencing Informs Genetic Testing in Breast Cancer

ALC1 Links Chromatin Accessibility to PARP Inhibitor Response in Homologous Recombination-Deficient Cells

Race Has No Place in Precision Oncology